CLL Trials in the United Kingdom the Medical Research Council CLL Trials 1, 2 and 3.

abstract：:Pulmonary marginal zone lymphoma is a rare disease arising from bronchial-associated lymphoid tissue (BALT). There is limited information on clinical presentation, natural history and treatment of this type of lymphoma. We conducted a retrospective review of patients with biopsy-proven BALT lymphoma treated at our ins...

journal_title：Leukemia & lymphoma

authors： Stefanovic A,Morgensztern D,Fong T,Lossos IS

更新日期：2008-07-01 00:00:00

abstract：:We have analyzed the co-expression of the bcr-abl and HoxA9 genes in the follow-up of patients with chronic myeloid leukemia (CML). In the present work we measured the HoxA9 and bcr-abl gene expression in sequential samples. In all patients, bcr-abl and HoxA9 were expressed at detectable levels in every sample. When t...

journal_title：Leukemia & lymphoma

authors： Tedeschi FA,Cardozo MA,Valentini R,Zalazar FE

更新日期：2010-05-01 00:00:00

abstract：:We describe a case of a patient with CD34+, TdT+, CD13-, CD33-, MPO- undifferentiated acute leukemia who refused chemotherapy and who achieved complete hematological remission 14 months after the diagnosis, during a short course of granulocyte-colony stimulating factor (G-CSF) for neutropenia and life threatening infe...

journal_title：Leukemia & lymphoma

authors： Xavier L,Cunha M,Gonçalves C,Teixeira Mdos A,Coutinho J,Ribeiro AC,Lima M

更新日期：2003-12-01 00:00:00

abstract：:Our aim was to describe a large population-based cohort of diffuse large B-cell lymphoma (DLBCL) during the last decade, evaluating possible improvement in survival and to identify subgroups in need of novel treatment strategies. The study population encompassed all patients diagnosed with DLBCL in Sweden from 2000 th...

journal_title：Leukemia & lymphoma

authors： Székely E,Hagberg O,Arnljots K,Jerkeman M

更新日期：2014-08-01 00:00:00

abstract：:Herbal remedies are clearly a complementary and alternative modality used frequently by patients with hemato-oncological neoplasias during the course of their specific treatment. This review focuses on the potential safety and efficacy of herbs which are either used often or even on a daily basis by patients with hema...

journal_title：Leukemia & lymphoma

authors： Ben-Arye E,Attias S,Tadmor T,Schiff E

更新日期：2010-08-01 00:00:00

abstract：:The relation between resistance to anticancer drugs and resistance to apoptosis has been investigated in the human leukemic cell line(KY-821) and its drug-resistant sublines. Under serum depletion conditions, drug-resistant cell lines showed apoptotic resistance when compared with the parental cell line. Drug resistan...

journal_title：Leukemia & lymphoma

authors： Kakihara T,Fukuda T,Kamishima T,Naito M,Tanaka A,Uchiyama M,Kishi K

更新日期：1997-07-01 00:00:00

abstract：:When lymph node biopsies of lymphocytic neoplasms are studied with subtle morphological and immunohistochemical methods meaningful information is obtained, that is not only of theoretical value, but which also relates to the clinical behavior ("leukemia," paraproteinemia, prognosis). Such an analysis allows us to diff...

journal_title：Leukemia & lymphoma

authors： Lennert K,Tamm I,Wacker HH

更新日期：1991-01-01 00:00:00

abstract：:Between 1985 and 1990, the French Cooperative Group on Chronic Lymphocytic Leukemia (CLL) randomized 287 stage B patients between intermittent chlorambucil plus prednisone (n = 140) or CHOP (n = 147), and 90 stage C patients between CHOP (n = 44) or CHOP plus methotrexate (n = 46). In stage B, although treatment respo...

journal_title：Leukemia & lymphoma

authors：

更新日期：1994-05-01 00:00:00

abstract：:Tumor-infiltrating immune cells perform a crucial function in host immune reactions against diffuse large B-cell lymphoma (DLBCL). In this study, we have identified a subset of tumor-infiltrating FOXP3-positive regulatory T cells (Tregs) in the initial DLBCL biopsy specimens, and have evaluated their prognostic signif...

journal_title：Leukemia & lymphoma

authors： Lee NR,Song EK,Jang KY,Choi HN,Moon WS,Kwon K,Lee JH,Yim CY,Kwak JY

更新日期：2008-02-01 00:00:00

abstract：:In acute myeloid leukemia (AML), cytogenetics predicts treatment outcome for the favorable and poor subgroups but not for the intermediate subgroup. Polymorphisms within the nucleotide excision repair (NER) pathway may lead to interindividual differences in DNA repair capacity, influencing outcome. We studied the role...

journal_title：Leukemia & lymphoma

authors： Strom SS,Estey E,Outschoorn UM,Garcia-Manero G

更新日期：2010-04-01 00:00:00

abstract：:Because of the lack of standard treatment in refractory and relapsed acute myelogenous leukemia (AML) several new drugs have been employed alone to evaluate their efficacy in this peculiar category of patient. Bisantrene, a new anthracene bishydrazone derivative, has shown antileukemic effect in phase I and II clinica...

journal_title：Leukemia & lymphoma

authors： Spadea A,Petti MC,Aloespiriti MA,Avvisati G,De Gregoris C,Fazi P,Latagliata R,Amadori S,Mandelli F

更新日期：1993-02-01 00:00:00

abstract：:This case is of an unusual florid reactive CD4+ T Cell lymphocytosis involving lymph node (LN) and overshadowing residual B chronic lymphocytic leukemia (CLL). A 65 year old female with a 9 year history of untreated B-CLL presented with weight loss, splenomegaly and lymphadenopathy. B-CLL was confirmed on the basis of...

journal_title：Leukemia & lymphoma

authors： Busmanis I,Hussein S,Feleppa F,Rockman S,Begley CG

更新日期：1993-01-01 00:00:00

abstract：:Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk leukemia that make them susceptible to high early mortality, chemotherapy-related toxicities, and poor long-term survival. The receipt of chemotherapy or hematopoietic cell transplantation is ...

journal_title：Leukemia & lymphoma

authors： Bhatt VR,Gundabolu K,Koll T,Maness LJ

更新日期：2018-01-01 00:00:00

abstract：:Using a non-myeloablative stem cell trasplantation (NST) program, 25 allografts were prospectively given to 24 patients with acute myelogenous leukemia (AML) eligible for conventional allografting; 2 individuals had secondary forms of AML. The median age of the patients was 35 years, with a range of 12 to 56. All pati...

journal_title：Leukemia & lymphoma

authors： Ruiz-Argüelles GJ,Gómez-Almaguer D,David-Gomez-Rangel J,Vela-Ojeda J,Cantú-Rodríguez OG,Jaime-Pérez JC,González-Llano O,Herrera-Garza JL

更新日期：2004-06-01 00:00:00

abstract：:The standard of therapy for the high risk adult neutropenic host being treated with broad spectrum antibiotics for fever has been to continue intravenous antibiotics until neutropenia resolves. We performed a small, limited pilot study to determine if it is safe to switch these patients to oral monotherapy with ciprof...

journal_title：Leukemia & lymphoma

authors： Horowitz HW,Holmgren D,Seiter K

更新日期：1996-09-01 00:00:00

abstract：:Patients with chronic lymphocytic leukemia (CLL) who fail fludarabine (Fluda) therapy have a poor response to subsequent salvage regimens and a poor prognosis. This study was undertaken to determine the efficacy and toxicity of a cis-platinum, (cis-p)fluda and arabinosyl cytosine (ara-C) combination in patients who we...

journal_title：Leukemia & lymphoma

authors： Giles FJ,O'Brien SM,Santini V,Gandhi V,Plunkett W,Seymour JF,Robertson LE,Kantarjian HM,Keating MJ

更新日期：1999-12-01 00:00:00

abstract：:The adenosine deaminase inhibitor 2'-deoxycoformycin (dCF) significantly inhibits the proliferation of leukemia and lymphoma cells in the presence of either 2'-deoxyadenosine (dAdo) or its analog adenine arabinoside (araA). The concentration of dCF required to induce apoptosis of monocytoid leukemia cells is much lowe...

journal_title：Leukemia & lymphoma

authors： Honma Y

更新日期：2001-09-01 00:00:00

abstract：:The overall cure rate of adults with newly-diagnosed acute myelogenous leukemia (AML) treated with continuous infusion high-dose cytarabine (CIHDAC) is comparable to that with standard-dose ara-C plus anthracycline or amsacrine (AMSA). We tested whether the addition of AMSA to CIH-DAC improves the outcome of adults wi...

journal_title：Leukemia & lymphoma

authors： Ghaddar HM,Pierce S,Kantarjian HM,Freireich EJ,Keating MJ,Estey EH

更新日期：1996-06-01 00:00:00

abstract：:Hepatocyte growth factor (HGF) was identified, purified and molecularly cloned as a potent mitogen for mature rat hepatocytes in primary culture. It is one of the largest cytokines and is composed of disulfide-linked subunits of approximately 60 (heavy chain) and 35 kilodaltons (light chain). Recent observations revea...

journal_title：Leukemia & lymphoma

authors： Gohda E,Nakamura S,Yamamoto I,Minowada J

更新日期：1995-10-01 00:00:00

abstract：:DNA methylation (DNAm) silences gene expression and may play a role in immune dysregulation that is characteristic of adolescent/young adult Hodgkin lymphoma (AYAHL). We used the Infinium HumanMethylation27 BeadChip to quantify DNAm in blood (N = 9 pairs, mean age 57.4 y) or saliva (N = 36 pairs, mean age 50.0 y) from...

journal_title：Leukemia & lymphoma

authors： Wang J,Van Den Berg D,Hwang AE,Weisenberger D,Triche T,Nathwani BN,Conti DV,Siegmund K,Mack TM,Horvath S,Cozen W

更新日期：2019-06-01 00:00:00

abstract：:Although BCR-ABL is the hallmark genetic abnormality of chronic myeloid leukemia (CML), secondary molecular events responsible for the evolution of the disease to blast crisis are yet to be deciphered. Taking into account the significant association of ecotropic viral integration site I (EVI1) in CML drug resistance, ...

journal_title：Leukemia & lymphoma

authors： Kuila N,Nayak KB,Halder A,Agatheeswaran S,Biswas G,Biswas S,Pattnayak NC,Chakraborty S

更新日期：2017-08-01 00:00:00

abstract：:Large granular lymphocyte disorder (LGLD) is a lymphoproliferative disease, characterized by moderate lymphocytosis with an excess of large granular lymphocytes, neutropenia, anemia, and a variable, but mostly chronic clinical course. We describe two patients with LGLD. One patient presented with symptomatic corticost...

journal_title：Leukemia & lymphoma

authors： Peller S,Kaufman S,Rotter V

更新日期：1991-01-01 00:00:00

abstract：:Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, an...

journal_title：Leukemia & lymphoma

authors： Sidiqi MH,Gertz MA

更新日期：2019-02-01 00:00:00

abstract：:We conducted a population-based study to assess how positron emission tomography (PET) is currently used in patients with Hodgkin lymphoma (HL). Four cancer registries from northern Italy were used to identify patients with HL diagnosed from 2006 to 2008. Computed tomography (CT) and PET scans were collected before tr...

journal_title：Leukemia & lymphoma

authors： Luminari S,Cesaretti M,Tomasello C,Guida A,Bagni B,Merli F,Postiglione R,Mangone L,Versari A,Re F,De Lisi V,Ruffini L,Ferretti S,Cuneo A,Federico M

更新日期：2011-09-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is characterized by the presence of chimeric protein BCR-ABL associated with high tyrosine kinase (TK) activity, which leads to cell tumorogenicity, resistance to apoptosis, and differentiation. Gossypol is a natural polyphenolic compound isolated from cottonseed and has antiproliferativ...

journal_title：Leukemia & lymphoma

authors： Meng Y,Li Y,Li J,Li H,Fu J,Liu Y,Liu H,Chen X

更新日期：2007-11-01 00:00:00

abstract：:Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare variant of Hodgkin's lymphoma (HL) in children. Since specific immunohistochemical staining has become available, NLPHL can be separated from classical Hodgkin's lymphoma (cHL) more accurately. Scarce information is available about pediatric NLPHL tre...

journal_title：Leukemia & lymphoma

authors： van Grotel M,Lam KH,de Man R,Beishuizen A,Pieters R,van den Heuvel-Eibrink MM

更新日期：2006-08-01 00:00:00

abstract：:In a prospective multicenter study 68 out of 158 patients with HIV infection and malignant lymphoma were assigned to a risk-adapted induction therapy using the following algorithm: High-risk patients fulfilled 2 of 3 criteria: T4 lymphocytes <50/microL; WHO activity index 3 or 4; pre-existing AIDS-defining opportunist...

journal_title：Leukemia & lymphoma

authors： Weiss R,Huhn D,Mitrou P,Nerl C,Schürmann D,Scheidegger C,Knauf W,Trenn G,Kronawitter U,Van Lunzen J,Arastéh K,Herbst H

更新日期：1998-03-01 00:00:00

abstract：:Twenty-nine patients with non-Hodgkin's lymphoma received a single subcutaneous injection of 6 mg pegfilgrastim approximately 24 h after the start of CHOP chemotherapy. The safety of pegfilgrastim in this patient population was determined by reports of adverse events. The pharmacokinetics of pegfilgrastim were charact...

journal_title：Leukemia & lymphoma

authors： George S,Yunus F,Case D,Yang BB,Hackett J,Shogan JE,Meza LA,Neumann TA,Liang BC

更新日期：2003-10-01 00:00:00

abstract：:In the rituximab era, several large studies have suggested that full-dose rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) might be the best treatment for patients with diffuse large B-cell lymphoma (DLBCL) aged 60 years and older. However, it remains unclear whether this is also the c...

journal_title：Leukemia & lymphoma

authors： Meguro A,Ozaki K,Sato K,Oh I,Fujiwara S,Hosonuma R,Sasazaki M,Kikuchi Y,Hirata Y,Yamamoto C,Uesawa M,Kobayashi H,Matsu H,Okabe H,Uehara E,Nishikawa A,Tatara R,Hatano K,Yamamoto C,Matsuyama T,Toshima M,Ueda M,O

更新日期：2012-01-01 00:00:00

abstract：:Classical Hodgkin's disease (HD) is a peculiar form of lymphoma characterized by a low frequency of tumor cells, the so-called Hodgkin (H) and Reed/Sternberg (RS) cells, embedded in a background of non-neoplastic (reactive) cells believed to be recruited and activated by H-RS cell-derived cytokines/chemokines. How the...

journal_title：Leukemia & lymphoma

authors： Aldinucci D,Olivo K,Lorenzon D,Poletto D,Gloghini A,Carbone A,Pinto A

更新日期：2005-03-01 00:00:00